Neuromeka Announces 150 Billion KRW Rights Offering - Aimed at Financial Restructuring and Facility Investment, Significant Dilution Risk
- Rights offering followed by public offering to raise 150 billion KRW (expected), issuing 2,982,109 new shares (24.12% increase over existing shares)
- 20% discount rate applied, expected issue price 50,300 KRW (23.5% discount from reference price of 65,793 KRW)
- Use of proceeds: facility investment 80 billion KRW (new Pohang plant), operating funds 60 billion KRW, debt repayment 10 billion KRW
- FY2025 consolidated revenue 19.0 billion KRW, operating loss 14.9 billion KRW, net loss 22.0 billion KRW (net profit margin -116.02%)
- Debt-to-equity ratio 557.63% at end-2025, current ratio 55.08% (below industry average)
- Debt-to-equity ratio improved to 101.14% in Q1 2026 (due to CB conversion into common shares)
- Negative operating cash flow for three consecutive years (2023: -12.4 billion, 2024: -21.9 billion, 2025: -11.4 billion KRW)
- Largest shareholder stake may drop from 18.39% to as low as 14.88% post-offering (weak management control)
- Potential further dilution from outstanding CBs (629,182 shares convertible) and stock options (124,465 shares)
- High deviation from IPO forecasts (2025 revenue forecast 57.3 billion vs actual 19.0 billion, achievement rate 33%)
- Accounts receivable turnover 2.57x (industry avg 4.79x), overdue >3 months 2.147 billion KRW (38.0%)
- Inventory turnover 1.85x (industry avg 5.00x), inventory 8.826 billion KRW
- R&D spending dependency on government grants 58.89% (2025)
- Listed as 'investment caution' 9 times, 'investment warning' 3 times, 'investment risk' 1 time since listing in 2022
- Concurrent bonus issue (0.5 shares per 1 share) → additional share count increase
- Risk of being selected for intensive review (poor financial performance, earnings miss) and designated as managed stock (recurring pre-tax losses)
- Underwriter assessment: positives (robot market growth, policy support, technology) vs negatives (persistent losses, high leverage, weak cash flow)
ADVERTISEMENT (250px+)
KOSDAQ Filing Information
- Filing: [Correction of Description] Securities Registration Statement (Equity Securities)
- Company: Neuromeka (348340)
- Submission: Neuromeka Co., Ltd.
- Receipt: 05-14-2026